MT-500 (POZEN).
MT-500 (formerly RS-127445) is a 5-HT2B antagonist being developed for the prophylactic treatment of migraine. POZEN acquired MT-500 from Roche in November 1999, and assumed full responsibility for its development for migraine propylaxis. Roche may elect to reacquire the compound at certain stages. The company expected to commence phase II trials during the first half of 2000 [348204]. POZEN has three other compounds, MT-400, MT-300 and MT-100, in phases I, II and III, respectively, for the treatment of acute migraine. Before outlicensing the compound, Roche Bioscience had completed phase I trials with MT-500 which indicate that it has a favorable side effect and safety profile [348204]. In January 2001, US Bancorp Piper Jaffray predicted phase II development beginning in 2001, with a launch in 2006 [396247].
Mucke
H A
HA
Pharmaceutical Consultant and Analyst, Wien, Austria. h.mucke@aon.at
D000818:Animals; D001007:Anxiety / Q000188:drug therapy; D017321:Clinical Trials, Phase I as Topic; D004353:Drug Evaluation, Preclinical; D015507:Drugs, Investigational; D006801:Humans; D008881:Migraine Disorders / Q000150:complications / Q000209:etiology / Q000517:prevention & control; D015394:Molecular Structure; D010330:Patents as Topic; D011743:Pyrimidines / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D011985:Receptors, Serotonin / Q000187:drug effects*; D012702:Serotonin Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D013997:Time Factors
D015507:Drugs, Investigational; D011743:Pyrimidines; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; C121466:2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine